|Articles|March 15, 2002

BioPharm International

  • BioPharm International-03-15-2002
  • Volume 15
  • Issue 3

Guest Editorial: Warning Letters ? A Symptom?

by Steven S. Kuwahara, Titan Pharmaceuticals Numerous warning letters and consent decrees have revealed problems in coping with even simple parts of the GMPs.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.